Session Synopsis: Historically genetic testing has been restricted to affected families due to the high cost of DNA sequencing. As costs come down we now have the capability to provide comprehensive genetic testing as part of health and prevention programs based on personal utility. This session explores the value and pitfalls of genetic testing in the healthy population.
Session Chair Profile
Randy Scott is co-founder, chairman and CEO of Invitae Corporation (NYSE: NVTA), a company focused on bringing comprehensive genetic information into routine medical practice to improve the quality of healthcare for billions of people by making genetic testing more affordable and accessible. Prior to starting Invitae, Dr. Scott founded Genomic Health (NASDAQ: GHDX) in 2000 and led the company as CEO for nine years with a focus on improving the quality of treatment decisions for patients with cancer. Dr. Scott has played a role in founding several successful biotech companies in addition to Genomic Health Inc., including Incyte (NASDAQ: INCY), a genomic information company. Dr. Scott, an author of more than 40 scientific publications, 20 patents, and recipient of numerous awards, holds a Bachelor of Science degree in Chemistry from Emporia State University and a Ph.D. in Biochemistry from the University of Kansas.
M.D., MPH, Associate Professor of Medicine, Harvard Medical School, Director, Genomes2People Research Program
Dr. Green is a medical geneticist and physician-scientist who is internationally recognized for designing and conducting empirical studies in genomic medicine. He currently leads and co-leads the MedSeq and BabySeq Projects, respectively, two NIH-funded randomized trials designed to explore the medical, behavioral and economic implications of integrating genome sequencing into the medical care of adults and newborns. Other noteworthy contributions include leading the first experimental trials to disclose genetic risk of common complex disease (the REVEAL Study) and one of the first prospective studies of direct-to-consumer genetic testing services (the PGen Study). He was the lead author on the influential recommendations for managing incidental findings in clinical sequencing from the American College of Medical Genetics and Genomics, and a co-author on recommendations for managing incidental genomic findings in research biobanks.
Genomic Sequencing in Healthy Individuals
Despite a proliferation of clinical and research programs offering predispositional genomic sequencing (PGS) to ostensibly healthy adults, the outcomes of providing this information remain unclear. Randomized clinical trials can help researchers explore the responsible integration of PGS into medical care.
M.D., Managing Partner, Private Medical
Jordan Shlain MD is a physician, entrepreneur, publisher and healthcare systems designer. He is the founder of Healthloop, the editor-in-chief at Tincture and a practicing primary care doctor with offices and partners in San Francisco, Silicon Valley and Los Angeles. His leadership has emphasized a fundamental redesign of how healthcare is delivered, utilized and understood in the context of proactive communication, individualized surveillance, shared-decision making, on-demand access and a deep sense of empathy and the human spirit. He is the founder and chairman of the Institute for Responsible Nutrition, a non-profit working to change our food composition to reduce the alarming trend of children getting ‘adult-onset’ diabetes as well as an active board member for the Washington DC based, Hope Street Group. In 2009, the mayor of San Francisco asked Dr. Shlain to serve on the San Francisco Health Commission where he oversaw an $800MM budget for 47,000 employees.
The Intersection of Primary Care & Genomics
The world of research is moving fast. The world of clinical medicine is moving slow. In the world of entrepreneurship and start-ups the mantra is move fast and break things…in the world of healthcare, it’s move slow and don’t kill people. For all the talk of data driven science, we need to be rational, realistic and reasonable when we begin to apply theory to reality. To quote Yogi Berra: In theory there is no difference between theory and practice. In practice there is. Genomics is coming, let’s be thoughtful in it’s application to practice.
Co-founder & SVP Corporate Dev., Helix
Justin is a Co-Founder at Helix, a personal genomics company dedicated to empowering every person to improve their life through DNA. Helix is creating an ecosystem where people can explore diverse and uniquely personalized applications powered by DNA insights and provided by high-quality partners. Prior to Helix, Justin was a Vice President in the healthcare group at Warburg Pincus, a global private equity firm focused on growth investing. Earlier in his career, he also spent time at the Boston Consulting Group, where he worked with a variety of companies in the tech and healthcare industries, and Onyx Pharmaceuticals, where he played a key role in the acquisition of Proteolix. Justin holds a B.S. in Chemical Engineering and a M.S. in Bioengineering from Stanford University. He also received a J.D. from Stanford Law School and a M.B.A. from Stanford Graduate School of Business, where he was an Arjay Miller Scholar.
The Future of Personal Genomics for All
DNA can power many aspects of every person’s life – yet the impact for most people has been limited. What will it take for personal genomics to help us lead better lives in areas as diverse as family planning, nutrition, fitness, health, ancestry, and even entertainment?